Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Edwards LifeSciences

This article was originally published in The Gray Sheet

Executive Summary

Company forecasts during its Dec. 11 analyst day in New York that sales of the Sapien transcatheter heart valve will reach $75 million-$95 million in 2009. Edwards also reaffirms it is on track to start U.S. clinical trials by the end of next year for its next-generation Sapien XT valve. The firm presented early European data on transfemoral delivery of Sapien at the Transcatheter Cardiovascular Therapeutics meeting in October (1"The Gray Sheet" Oct. 20, 2008, p. 16). Edwards' total heart valve therapy business is anticipated to grow 14%-16% in 2009 to $640 million-$670 million. Corporate sales are forecast at $1.24 billion-$1.3 billion

You may also be interested in...



Vying Valves: Edwards’ Sapien Progresses, But CoreValve Remains A Threat

European data for Edwards Lifesciences' Sapien transcatheter heart valve are encouraging, but analysts have raised questions about design of the firm's planned U.S. trial of the device

‘Supplement’ On CBD Product Label A Bullseye For US Litigants, Says Attorney

Two CBD marketers warned by FDA in a recent crackdown are targeted in class action complaints alleging they made unsubstantiated health claims and mislabeled ‘illegal drug’ products as supplements. Complaints are a wake-up call to CBD wellness industry to ensure claims are substantiated, as the class action bar is on the prowl following the agency’s 15 warning letter blast in November.

HBW Market News: GNC US Chief, Clasado Commercial Head, Barentz Funding

GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.

UsernamePublicRestriction

Register

MT026888

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel